Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (8): 872-876.doi: 10.11958/20231919
• Clinical Research • Previous Articles Next Articles
SUN Yanwen(), WANG Cong, CHEN Shiliang, ZHANG Ranran△(
)
Received:
2023-12-09
Revised:
2024-01-11
Published:
2024-08-15
Online:
2024-08-16
Contact:
E-mail:SUN Yanwen, WANG Cong, CHEN Shiliang, ZHANG Ranran. Analysis of dyslipidemia associated with myelodysplastic syndrome[J]. Tianjin Medical Journal, 2024, 52(8): 872-876.
CLC Number:
组别 | n | 年龄/岁 | 性别(男/女) | BMI/(kg/m2) |
---|---|---|---|---|
对照组 | 100 | 59.45±14.08 | 58/42 | 23.18±3.65 |
研究组 | 88 | 60.27±13.84 | 55/33 | 23.68±3.90 |
t或χ2 | 0.403 | 0.395 | 0.903 | |
组别 | TG/(mmol/L) | TC/(mmol/L) | HDL-C/(mmol/L) | |
对照组 | 1.50(0.10,2.18) | 4.84(4.23,5.60) | 1.24±0.23 | |
研究组 | 1.17(0.85,2.07) | 2.74(2.18,3.70) | 0.86±0.26 | |
t或Z | 1.867 | 9.391** | 10.628** | |
组别 | LDL-C/(mmol/L) | ApoA1/(mmol/L) | ApoB/(mmol/L) | |
对照组 | 2.61(1.97,3.23) | 1.43±0.16 | 1.00(0.79,1.19) | |
研究组 | 1.57(1.07,2.12) | 1.09±0.28 | 0.66(0.53,0.82) | |
t或Z | 7.271** | 10.233** | 8.212** |
Tab.1 Comparison of demographic characteristics and blood lipid levels between the study group and the control group
组别 | n | 年龄/岁 | 性别(男/女) | BMI/(kg/m2) |
---|---|---|---|---|
对照组 | 100 | 59.45±14.08 | 58/42 | 23.18±3.65 |
研究组 | 88 | 60.27±13.84 | 55/33 | 23.68±3.90 |
t或χ2 | 0.403 | 0.395 | 0.903 | |
组别 | TG/(mmol/L) | TC/(mmol/L) | HDL-C/(mmol/L) | |
对照组 | 1.50(0.10,2.18) | 4.84(4.23,5.60) | 1.24±0.23 | |
研究组 | 1.17(0.85,2.07) | 2.74(2.18,3.70) | 0.86±0.26 | |
t或Z | 1.867 | 9.391** | 10.628** | |
组别 | LDL-C/(mmol/L) | ApoA1/(mmol/L) | ApoB/(mmol/L) | |
对照组 | 2.61(1.97,3.23) | 1.43±0.16 | 1.00(0.79,1.19) | |
研究组 | 1.57(1.07,2.12) | 1.09±0.28 | 0.66(0.53,0.82) | |
t或Z | 7.271** | 10.233** | 8.212** |
组别 | n | TG | TC | HDL-C | LDL-C | ApoA1 | ApoB |
---|---|---|---|---|---|---|---|
MDS分型 | |||||||
MDS-SLD | 5 | 1.90(0.96,33.50) | 2.35(1.38,3.35) | 0.88(0.71,0.97) | 2.04(1.17,2.20) | 1.08(0.96,1.21) | 0.73(0.56,0.82) |
MDS-MLD | 23 | 1.18(0.86,1.66) | 2.50(2.14,3.73) | 0.78(0.66,1.06) | 1.34(0.98,2.47) | 1.22(0.96,1.32) | 0.65(0.52,0.83) |
MDS-RS | 4 | 0.98(0.52,1.43) | 3.61(2.63,4.86) | 0.96(0.69,1.25) | 1.90(1.20,2.86) | 0.94(0.89,1.16) | 0.77(0.60,0.98) |
MDS-EB1 | 22 | 1.22(0.69,2.28) | 2.62(1.91,4.07) | 0.81(0.61,0.92) | 1.53(1.11,1.90) | 1.00(0.81,1.82) | 0.68(0.56,0.82) |
MDS-EB2 | 18 | 0.97(0.80,1.66) | 2.93(2.47,3.46) | 0.81(0.68,1.16) | 1.59(1.31,1.87) | 1.12(0.82,1.31) | 0.66(0.62,0.75) |
MDS-U | 12 | 1.10(0.89,2.36) | 2.74(2.18,3.47) | 0.96(0.78,1.04) | 1.52(1.09,1.95) | 1.23(1.12,1.35) | 0.65(0.49,0.98) |
MDS转AML | 4 | 1.18(1.23,2.07) | 2.87(2.27,4.74) | 0.69(0.45,0.89) | 1.40(0.94,2.30) | 0.72(0.60,1.10) | 0.68(0.49,0.98) |
χ2 | 4.607 | 4.284 | 5.397 | 1.239 | 10.568 | 2.395 | |
IPSS-R危险度 | |||||||
低危组 | 21 | 1.18(0.97,3.14) | 2.59(1.73,2.98) | 0.83(0.71,1.08) | 1.40(0.99,2.10)) | 1.12(0.96,1.45) | 0.63(0.51,0.78) |
中危组 | 29 | 1.26(0.85,1.96) | 3.18(2.44,3.74) | 0.90(0.73,0.98) | 1.83(1.30,2.24) | 1.16(0.97,1.25) | 0.69(0.55,0.85) |
高危组 | 37 | 0.98(0.79,1.88) | 2.56(2.17,3.77) | 0.70(0.59,1.06) | 1.54(1.02,2.02) | 0.95(0.76,1.26)a | 0.66(0.54,0.81) |
χ2 | 2.224 | 3.001 | 4.004 | 2.571 | 6.813* | 2.054 | |
IPSS-R核型 | |||||||
良好组 | 57 | 1.19(0.85,2.78) | 2.87(2.23,3.77) | 0.87(0.71,1.04) | 1.68(1.29,2.21) | 1.11(0.96,1.28) | 0.72(0.59,0.83) |
中等组 | 11 | 1.26(1.16,2.30) | 2.45(2.18,3.36) | 0.70(0.51,1.03) | 1.32(0.99,1.58) | 0.97(0.78,1.28) | 0.60(0.47,0.79) |
差组 | 4 | 0.91(0.82,2.01) | 2.29(1.65,3.24) | 0.88(0.74,0.97) | 1.17(0.75,1.74) | 1.07(0.87,1.42) | 0.57(0.45,0.76) |
极差组 | 15 | 0.95(0.67,1.26) | 2.48(2.02,3.36) | 0.70(0.53,1.07) | 1.05(0.92,1.86) | 0.77(0.74,1.24) | 0.64(0.47,0.70) |
χ2 | 6.060 | 2.958 | 4.138 | 7.618 | 6.677 | 6.515 | |
TP53突变 | |||||||
非突变组 | 36 | 1.18(0.87,2.36) | 3.00(2.20,3.75) | 0.90(0.71,1.08) | 1.68(1.10,2.21) | 1.22(0.95,1.29) | 0.68(0.54,0.82) |
突变组 | 24 | 1.04(0.89,1.65) | 2.55(2.18,3.22) | 0.72(0.56,0.99) | 1.38(0.99,1.82) | 0.96(0.74,1.21) | 0.65(0.51,0.72) |
Z | 0.543 | 0.905 | 1.909 | 1.720 | 2.460* | 0.974 |
Tab.2 Comparison of blood lipid levels in MDS patients with different disease states
组别 | n | TG | TC | HDL-C | LDL-C | ApoA1 | ApoB |
---|---|---|---|---|---|---|---|
MDS分型 | |||||||
MDS-SLD | 5 | 1.90(0.96,33.50) | 2.35(1.38,3.35) | 0.88(0.71,0.97) | 2.04(1.17,2.20) | 1.08(0.96,1.21) | 0.73(0.56,0.82) |
MDS-MLD | 23 | 1.18(0.86,1.66) | 2.50(2.14,3.73) | 0.78(0.66,1.06) | 1.34(0.98,2.47) | 1.22(0.96,1.32) | 0.65(0.52,0.83) |
MDS-RS | 4 | 0.98(0.52,1.43) | 3.61(2.63,4.86) | 0.96(0.69,1.25) | 1.90(1.20,2.86) | 0.94(0.89,1.16) | 0.77(0.60,0.98) |
MDS-EB1 | 22 | 1.22(0.69,2.28) | 2.62(1.91,4.07) | 0.81(0.61,0.92) | 1.53(1.11,1.90) | 1.00(0.81,1.82) | 0.68(0.56,0.82) |
MDS-EB2 | 18 | 0.97(0.80,1.66) | 2.93(2.47,3.46) | 0.81(0.68,1.16) | 1.59(1.31,1.87) | 1.12(0.82,1.31) | 0.66(0.62,0.75) |
MDS-U | 12 | 1.10(0.89,2.36) | 2.74(2.18,3.47) | 0.96(0.78,1.04) | 1.52(1.09,1.95) | 1.23(1.12,1.35) | 0.65(0.49,0.98) |
MDS转AML | 4 | 1.18(1.23,2.07) | 2.87(2.27,4.74) | 0.69(0.45,0.89) | 1.40(0.94,2.30) | 0.72(0.60,1.10) | 0.68(0.49,0.98) |
χ2 | 4.607 | 4.284 | 5.397 | 1.239 | 10.568 | 2.395 | |
IPSS-R危险度 | |||||||
低危组 | 21 | 1.18(0.97,3.14) | 2.59(1.73,2.98) | 0.83(0.71,1.08) | 1.40(0.99,2.10)) | 1.12(0.96,1.45) | 0.63(0.51,0.78) |
中危组 | 29 | 1.26(0.85,1.96) | 3.18(2.44,3.74) | 0.90(0.73,0.98) | 1.83(1.30,2.24) | 1.16(0.97,1.25) | 0.69(0.55,0.85) |
高危组 | 37 | 0.98(0.79,1.88) | 2.56(2.17,3.77) | 0.70(0.59,1.06) | 1.54(1.02,2.02) | 0.95(0.76,1.26)a | 0.66(0.54,0.81) |
χ2 | 2.224 | 3.001 | 4.004 | 2.571 | 6.813* | 2.054 | |
IPSS-R核型 | |||||||
良好组 | 57 | 1.19(0.85,2.78) | 2.87(2.23,3.77) | 0.87(0.71,1.04) | 1.68(1.29,2.21) | 1.11(0.96,1.28) | 0.72(0.59,0.83) |
中等组 | 11 | 1.26(1.16,2.30) | 2.45(2.18,3.36) | 0.70(0.51,1.03) | 1.32(0.99,1.58) | 0.97(0.78,1.28) | 0.60(0.47,0.79) |
差组 | 4 | 0.91(0.82,2.01) | 2.29(1.65,3.24) | 0.88(0.74,0.97) | 1.17(0.75,1.74) | 1.07(0.87,1.42) | 0.57(0.45,0.76) |
极差组 | 15 | 0.95(0.67,1.26) | 2.48(2.02,3.36) | 0.70(0.53,1.07) | 1.05(0.92,1.86) | 0.77(0.74,1.24) | 0.64(0.47,0.70) |
χ2 | 6.060 | 2.958 | 4.138 | 7.618 | 6.677 | 6.515 | |
TP53突变 | |||||||
非突变组 | 36 | 1.18(0.87,2.36) | 3.00(2.20,3.75) | 0.90(0.71,1.08) | 1.68(1.10,2.21) | 1.22(0.95,1.29) | 0.68(0.54,0.82) |
突变组 | 24 | 1.04(0.89,1.65) | 2.55(2.18,3.22) | 0.72(0.56,0.99) | 1.38(0.99,1.82) | 0.96(0.74,1.21) | 0.65(0.51,0.72) |
Z | 0.543 | 0.905 | 1.909 | 1.720 | 2.460* | 0.974 |
指标 | r/rs | 指标 | r/rs | |
---|---|---|---|---|
性别 | 0.200 | 血小板 | -0.025 | |
年龄 | -0.226* | 铁蛋白 | 0.102 | |
病程 | -0.550 | 乳酸脱氢酶 | 0.185 | |
BMI | 0.292* | IPSS-R核型 | -0.255* | |
骨髓原始细胞百分比 | -0.278* | IPSS-R危险度 | -0.280* | |
白细胞总数 | -0.017 | 心血管疾病 | -0.054 | |
中性粒细胞总数 | 0.013 | MDS转白血病 | -0.143 | |
外周血幼稚细胞百分比 | -0.151 | MDS分型 | -0.016 | |
血红蛋白 | 0.042 | TP53基因突变 | -0.320* |
Tab.3 The correlation analysis between ApoA1 levels and clinical factors in MDS patients
指标 | r/rs | 指标 | r/rs | |
---|---|---|---|---|
性别 | 0.200 | 血小板 | -0.025 | |
年龄 | -0.226* | 铁蛋白 | 0.102 | |
病程 | -0.550 | 乳酸脱氢酶 | 0.185 | |
BMI | 0.292* | IPSS-R核型 | -0.255* | |
骨髓原始细胞百分比 | -0.278* | IPSS-R危险度 | -0.280* | |
白细胞总数 | -0.017 | 心血管疾病 | -0.054 | |
中性粒细胞总数 | 0.013 | MDS转白血病 | -0.143 | |
外周血幼稚细胞百分比 | -0.151 | MDS分型 | -0.016 | |
血红蛋白 | 0.042 | TP53基因突变 | -0.320* |
组别 | n | 性别(男/女) | 年龄/岁 | BMI/(kg/m2) | 骨髓原始细胞百分比/% | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
低ApoA1组 | 44 | 31/13 | 63.16±11.08 | 23.00(20.25,24.83) | 4.00(1.00,9.38) | |||||||||
高ApoA1组 | 44 | 24/20 | 57.39±15.74 | 24.09(22.48,26.65) | 0.05(0.00,10.25) | |||||||||
t、χ2或Z | 2.376 | 1.990 | 2.141* | 2.045* | ||||||||||
组别 | IPSS-R核型 | IPSS-R危险度 | TP53基因突变 | |||||||||||
良好 | 中等 | 差 | 极差 | 低危 | 中危 | 高危 | 未突变 | 突变 | ||||||
低ApoA1组 | 25(58.1) | 6(14.0) | 2(4.7) | 10(23.3) | 9(20.9) | 11(25.6) | 23(53.5) | 14(46.7) | 16(53.3) | |||||
高ApoA1组 | 32(72.7) | 5(11.4) | 2(4.5) | 5(11.4) | 12(27.3) | 18(40.9) | 14(31.8) | 22(73.3) | 8(26.7) | |||||
χ2 | 2.606 | 4.296 | 4.444* |
Tab.4 Comparison of clinical factors between the two groups of MDS patients
组别 | n | 性别(男/女) | 年龄/岁 | BMI/(kg/m2) | 骨髓原始细胞百分比/% | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
低ApoA1组 | 44 | 31/13 | 63.16±11.08 | 23.00(20.25,24.83) | 4.00(1.00,9.38) | |||||||||
高ApoA1组 | 44 | 24/20 | 57.39±15.74 | 24.09(22.48,26.65) | 0.05(0.00,10.25) | |||||||||
t、χ2或Z | 2.376 | 1.990 | 2.141* | 2.045* | ||||||||||
组别 | IPSS-R核型 | IPSS-R危险度 | TP53基因突变 | |||||||||||
良好 | 中等 | 差 | 极差 | 低危 | 中危 | 高危 | 未突变 | 突变 | ||||||
低ApoA1组 | 25(58.1) | 6(14.0) | 2(4.7) | 10(23.3) | 9(20.9) | 11(25.6) | 23(53.5) | 14(46.7) | 16(53.3) | |||||
高ApoA1组 | 32(72.7) | 5(11.4) | 2(4.5) | 5(11.4) | 12(27.3) | 18(40.9) | 14(31.8) | 22(73.3) | 8(26.7) | |||||
χ2 | 2.606 | 4.296 | 4.444* |
[1] | PONTRELLI G, LOSCALZO C, L'EPLATTENIER M. An overview of myelodysplastic syndromes[J]. JAAPA, 2023, 36(6):17-21. doi:10.1097/01.JAA.0000931428.87936.72. |
[2] | RAMOS F. Myelodysplastic syndrome:riding the crest of the wave[J]. J Clin Med, 2022, 11(6):1606. doi:10.3390/jcm11061606. |
[3] | 唐豪言, 潘正龙, 刘小方. TP53基因单核苷酸多态性与原发性肝细胞癌预后的关系[J]. 天津医药, 2023, 51(11):1249-1254. |
TANG H Y, PAN Z L, LIU X F. Association between single nucleotide polymorphism of TP53 gene and prognosis of primary hepatocellular carcinoma[J]. Tianjin Med J, 2023, 51(11):1249-1254. doi:10.11958/20230151. | |
[4] | CHENG H, WANG M, SU J, et al. Lipid metabolism and cancer[J]. Life(Basel), 2022, 12(6):784. doi:10.3390/life12060784. |
[5] | 黄思思, 王智沁, 杨勇文, 等. 骨髓增生异常综合征患者血脂代谢特点分析[J]. 中国医学工程, 2021, 29(5):1-4. |
HUANG S S, WANG Z Q, YANG Y W, et al. Serum lipid profile in patients with myelodysplastic syndromes[J]. China Medical Engineering, 2021, 29(5):1-4. doi:10.19338/j.issn.1672-2019.2021.05.001. | |
[6] | ELLIS M H, BARAF L, SHAISH A, et al. Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway[J]. Exp Hematol, 2012, 40(7):540-547.e1. doi:10.1016/j.exphem.2012.02.003. |
[7] | ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405. doi:10.1182/blood-2016-03-643544. |
[8] | SNAEBJORNSSON M T, JANAKI-RAMAN S, SCHULZE A. Greasing the wheels of the cancer machine:the role of lipid metabolism in cancer[J]. Cell Metab, 2020, 31(1):62-76. doi:10.1016/j.cmet.2019.11.010. |
[9] | GARRIDO M M, MARTA J C, RIBEIRO R M, et al. Serum lipids and prostate cancer[J]. J Clin Lab Anal, 2021, 35(4):e23705. doi:10.1002/jcla.23705. |
[10] | STUANI L, RIOLS F, MILLARD P, et al. Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid leukemia[J]. Int J Mol Sci, 2018, 19(11):3325. doi:10.3390/ijms19113325. |
[11] | QIAO W, YOUNG E, FENG C, et al. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia[J]. Exp Hematol Oncol, 2022, 11(1):58. doi:10.1186/s40164-022-00309-7. |
[12] | ALLAMPALLAM K, DUTT D, NAIR C, et al. The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes[J]. J Hematother Stem Cell Res, 2000, 9(2):247-255. doi:10.1089/152581600319469. |
[13] | EFFICACE F, COTTONE F, OSWALD L B, et al. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index[J]. Leukemia, 2020, 34(9):2451-2459. doi:10.1038/s41375-020-0746-8. |
[14] | COCHRAN B J, ONG K L, MANANDHAR B, et al. APoa1:a protein with multiple therapeutic functions[J]. Curr Atheroscler Rep, 2021, 23(3):11. doi:10.1007/s11883-021-00906-7. |
[15] | SHAFAT M S, OELLERICH T, MOHR S, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment[J]. Blood, 2017, 129(10):1320-1332. doi:10.1182/blood-2016-08-734798. |
[16] | PARRALES A, IWAKUMA T. p53 as a regulator of lipid metabolism in cancer[J]. Int J Mol Sci, 2016, 17(12):2074. doi:10.3390/ijms17122074. |
[17] | ASHUR-FABIAN O, HAR-ZAHAV A, SHAISH A, et al. apoB and apobec1,two genes key to lipid metabolism,are transcriptionally regulated by p53[J]. Cell Cycle, 2010, 9(18):3761-3770. |
[18] | 汪勇, 丁凯阳, 汪琼, 等. TP53基因突变骨髓增生异常综合征患者预后观察[J]. 皖南医学院学报, 2021, 40(3):225-228. |
WANG Y, DING K Y, WANG Q, et al. Observation on the prognosis in patients of myelodysplastic syndrome with TP53 mutation[J]. Acta Academiae Medicinae Wannan, 2021, 40(3):225-228. doi:10.3969/j.issn.1002-0217.2021.03.006. | |
[19] | CUMBO C, TOTA G, ANELLI L, et al. TP53 in myelodysplastic syndromes:recent biological and clinical findings[J]. Int J Mol Sci, 2020, 21(10):3432. doi:10.3390/ijms21103432. |
[20] | SHI W, WU S, SUN T, et al. Risk factors to predict ocular metastasis in older adult patients with gastric cancer:LDL,ApoA1,and CA724[J]. Technology in Cancer Research & Treatment, 2022,21:153303382110658. doi:10.1177/15330338211065876. |
[21] | NISHIYAMA H, FUNAMIZU T, IWATA H, et al. Low apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention:a 10-year follow-up study[J]. Int J Cancer, 2022, 151(9):1482-1490. doi:10.1002/ijc.34164. |
[22] | YUN X, SUN X, HU X, et al. Prognostic and therapeutic value of apolipoprotein a and a new risk scoring system based on apolipoprotein a and adenosine deaminase in chronic lymphocytic leukemia[J]. Front Oncol, 2021, 11:698572. doi:10.3389/fonc.2021.698572. |
[1] | LIU Qingqing, LI Yiqiang, SHI Yushi, LU Haisong, CHENG Weimin. Research progress on the mechanism of the TGF-β signaling pathway in myelodysplastic syndrome [J]. Tianjin Medical Journal, 2024, 52(7): 781-784. |
[2] | JI Zhen, LI Xiaozhou, WANG Xiuyan, LIU Lanze, MENG Fanrong, JU Duan. Application of low depth whole genome sequencing technology in the diagnosis of genetic etiology of recurrent spontaneous abortion [J]. Tianjin Medical Journal, 2024, 52(5): 490-494. |
[3] | BAI Mengke, YANG Xiaoqing, MEI Xiaofeng, LI Jin’gang, ZHANG Qiushuang, HUANG Yanjie. Analysis of the urinary protein and pathological characteristics of IgA vasculitis with nephritis in children with dyslipidemia [J]. Tianjin Medical Journal, 2023, 51(7): 751-755. |
[4] | ZHANG Ying, SHAO Dujing, LIU Xiaogang, ZHAO Yingqiang, LIU Yujie . Clinical study of cardiovascular protective effect of Qishen yiqi dropping pills on patients with hypertension complicated by coronary heart disease #br# [J]. Tianjin Medical Journal, 2022, 50(2): 177-181. |
[5] | PENG Jun-hua, GE Suo-hua, ZHANG Huan-yan, YU Xue-bing, SUN Lu-yang. The influence of shenling baizhu powder and metformin on miR-146a, GLP-1 and blood lipid in type 2 diabetes mellitus obesity #br# [J]. Tianjin Medical Journal, 2021, 49(2): 203-207. |
[6] | ZHUO Lin, CAI Ting, CHEN Si-ting, WANG Xiu-ying, ZHUO Lang, CUI Jing-qiu. Study on related factors and effect relationship of abnormal plasma viscosity in health check-up participants [J]. Tianjin Medical Journal, 2021, 49(11): 1184-1188. |
[7] | LI Xiao-shuang, MA Fei, SUN Xiao-ying, LIU Chang, HAO Jing-hong. The effect of dyslipidemia on liver function after the first chemotherapy in breast cancer patients [J]. Tianjin Medical Journal, 2021, 49(10): 1081-1085. |
[8] | SONG Li, LIU Yang, WANG Dan. One case of first and second branchial arch syndrome in neonates [J]. Tianjin Medical Journal, 2019, 47(3): 290-292. |
[9] | XIA Chen-xi, WEI Dong, HUANG Bin, ZHOU Zheng-yang, LI Hong-yu. The relationship between subclinical hypothyroidism and visceral adipose tissue [J]. Tianjin Medical Journal, 2018, 46(9): 959-962. |
[10] | SHAO Zong-hong, WANG Hua-quan. Precision diagnosis and therapy of myelodysplastic syndrome based on disease nature and our facility [J]. Tianjin Med J, 2018, 46(8): 785-788. |
[11] | LYU Yang-yang, ZHAO Zhi-gang. Bone marrow microenvironment and myelodysplastic syndrome [J]. Tianjin Med J, 2018, 46(8): 842-846. |
[12] | ZHANG Rui 1,LIU Dai-hong2△. The challenge for allogeneic hematopoietic stem cell transplantation in acute leukemia/ myelodyplastic syndrom with TP53, TET2 or DNMT3A gene mutations [J]. Tianjin Med J, 2018, 46(8): 837-841. |
[13] | WANG Hua-quan, LIU Jia-xi. Mechanisms and therapies of thrombocytopenia in myelodysplastic syndrome [J]. Tianjin Med J, 2018, 46(8): 789-794. |
[14] | HAN Bing, LI Hong-min, CHEN Fang-fei, WU Jie. Etiology and treatment strategies of anemia in myelodysplastic syndromes [J]. Tianjin Med J, 2018, 46(8): 794-798. |
[15] | TONG Hong-yan. The risk factors and therapeutic strategies of infection in patients with myelodysplastic syndromes [J]. Tianjin Med J, 2018, 46(8): 799-803. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||